Skip to content

Peptides, hormones and pipeline drugs

Maridebart cafraglutide (MariTide)

MariTide is an investigational Amgen injection, given monthly or less often, that activates the GLP-1 receptor while blocking the GIP receptor.

Clinician review pending Updated Peptides, hormones and pipeline drugs
DefinitionMariTide is an investigational Amgen injection, given monthly or less often, that activates the GLP-1 receptor while blocking the GIP receptor.

What it means

MariTide links two GLP-1 peptides to an antibody that blocks the GIP receptor. That is the opposite GIP approach from tirzepatide, which activates GIP. Researchers are still debating why both approaches seem to help weight loss. The antibody design gives it a long half-life, allowing monthly or less frequent dosing.

In a phase 2 trial published in NEJM in 2025, adults with obesity without diabetes lost about 12% to 16% of body weight on average at 52 weeks across doses, compared with about 2.5% on placebo. Stomach side effects were common, especially when people started at higher doses without stepping up.

Amgen's phase 3 program is called MARITIME. MariTide was not FDA-approved at our last review and is available only in clinical trials.

Why it matters

If approved, MariTide could change dosing from weekly to monthly, which matters for people who struggle with frequent shots.

Related terms

GIPGLP-1 receptor agonistHalf-lifeTitration

Sources

  1. MariTide phase 2 trial (NEJM, 2025)
  2. ClinicalTrials.gov: maridebart cafraglutide

Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error